Background: Evidence suggests that Candida can be sexually transmitted; however, the contribution of sexual transmission to the pathogenesis of genital candidosis needs further elucidation.
Objective: The aim was to evaluate genital candidosis and its transmissibility in heterosexual couples.
Methods: Heterosexual couples were recruited among attendees of an Sexually Transmitted Diseases clinic. Specimens for yeast culture were collected from the glans penis and inner preputial layer using direct impression on CHROMagar Candida medium; vaginal exudates were collected using a cotton swab with subsequent inoculation on CHROMagar Candida medium. Mitochondrial DNA restriction analysis was performed to compare Candida isolates from both partners.
Results: A total of 64 couples were enrolled in the study. Frequency of sexual intercourse was significantly higher in couples where both partners yielded positive cultures and with at least one having genital candidosis (Odds ratios: 6.844; 95% CI 1.408-33.266). The same Candida species was found in both partners in 25% (16/64) of all couples but only 17.2% (11/64) were genetically similar. In total 12 of the 34 women suffering from vulvovaginal candidosis (VVC) had recurrent VVC (RVVC); two sexual partners of RVVC women (16.7%) had candida positive cultures, compared with 15 (68.2%) sexual partners of non RVVC women (Odds ratios: 0.093; 95% CI 0.016-0.544).
Conclusions: Only in a few heterosexual couples a genetic similarity of Candida species recovered from both partners was found. RVVC women were more likely to have an asymptomatic candida negative sexual partner. This study suggests that male genitalia do not represent a relevant reservoir for RVVC; thus, the relevance of sexual transmission should not be emphasized.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1468-3083.2010.03721.x | DOI Listing |
Microbiol Spectr
January 2025
Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
The lack of clinical breakpoints and epidemiological cut-off values (ECOFFs) for antifungals prescribed for vulvovaginal candidiasis (VVC) make interpretation of antifungal susceptibility data difficult. This leads to empirical prescribing, poor clinical management and emergence of resistance. The susceptibilities of 152 , 105 , 31 and 8 VVC isolates against eight antifungals, were determined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) E.
View Article and Find Full Text PDFVirulence
December 2025
Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, T he Netherlands.
Vulvovaginal candidiasis (VVC) is one of the most common infections caused by . VVC is characterized by an inadequate hyperinflammatory response and clinical symptoms associated with colonization of the vaginal mucosa. Compared to other host niches in which can cause infection, the vaginal environment is extremely rich in lactic acid that is produced by the vaginal microbiota.
View Article and Find Full Text PDFJ Am Acad Dermatol
January 2025
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Mycoses
January 2025
Department of Clinical Microbiology, General Hospital "G. Gennimatas", Athens, Greece.
Background: The epidemiology of vulvovaginal candidiasis (VVC) in Greece remains poorly reported and outdated.
Objectives: We therefore conducted a 2-year retrospective survey to assess the epidemiological aspects of the infection among symptomatic Greek patients.
Patients/methods: High vaginal swab samples were collected from adult women with clinically suspected VVC attending a private diagnostic laboratory in Athens.
Lasers Med Sci
January 2025
University of Campinas, Campinas, Brazil.
Purpose: RVVC is defined as four or more episodes of candidiasis in a 12-month period. Conventional treatment is complex and often involves long-term medication use or multiple treatments. ABL therapy is a promising treatment option as it is acceptable to women and has only rare side effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!